68Ga-DOTATATE PET/CT 与 123I-MIBG SPECT/CT 在神经母细胞瘤及节细胞神经母细胞瘤中枢神经系统转移中的头对头前瞻性对比分析
前瞻性纳入41例疑似中枢神经系统转移的神经母细胞瘤及节细胞神经母细胞瘤患者,均在一周内完成配对123I-MIBG SPECT/CT与68Ga-DOTATATE PET/CT检查。68Ga-DOTATATE PET/CT在患者、病灶及区域层面诊断效能均优于123I-MIBG SPECT/CT,并使51%(21/41)患者的临床管理决策发生改变。
要点
- 68Ga-DOTATATE PET/CT在中枢神经系统转移检测的患者、病灶及区域层面均优于123I-MIBG SPECT/CT。
- 68Ga-DOTATATE PET/CT结果使51%(21/41)患者的临床管理决策发生改变。
- 40/41例(98%)患者经确认存在中枢神经系统转移,确诊时平均年龄63个月(范围8–122个月)。
核心结论
- 68Ga-DOTATATE PET/CT在神经母细胞瘤及节细胞神经母细胞瘤中枢神经系统转移患者中表现出优异的诊断效能。
- 68Ga-DOTATATE PET/CT的检查结果使51%患者的治疗管理发生改变。
研究设计与样本
- 前瞻性研究纳入41例疑似中枢神经系统转移的神经母细胞瘤及节细胞神经母细胞瘤患者。
- 所有患者均在一周内完成配对123I-MIBG SPECT/CT与68Ga-DOTATATE PET/CT检查(中位间隔3天,范围1–7天)。
- 在患者、病灶及区域层面评估并比较两种影像方法的诊断效能。
- 分析临床管理决策改变组与未改变组之间患者特征的差异,组间比较采用独立样本t检验、χ2检验、Fisher精确检验及Mann-Whitney U检验。
主要发现
- 40/41例(98%)患者经确认存在中枢神经系统转移。
- 中枢神经系统转移确诊时平均年龄为63个月(范围8–122个月)。
- 68Ga-DOTATATE PET/CT在患者、病灶及区域层面的中枢神经系统转移检测中均优于123I-MIBG SPECT/CT。
- 68Ga-DOTATATE PET/CT结果使51%(21/41)患者的临床管理发生改变,主要归因于相较123I-MIBG SPECT/CT的新发或意外发现。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess and compare the diagnostic performance of Gallium-68 DOTA-Tyr3-octreotate positron emission tomography/computed tomography (68Ga-DOTATATE PET/CT) and Iodine-123 metaiodobenzylguanidine single photon emission computed tomography/computed tomography (123I-MIBG SPECT/CT) in detecting central nervous system (CNS) metastases of neuroblastoma (NB) and ganglioneuroblastoma (GNB), as well as to evaluate their impact on therapeutic management. METHODS: This prospective study enrolled 41 patients with NB and GNB who were suspected of having CNS metastases. All patients underwent paired 123I-MIBG SPECT/CT and 68Ga-DOTATATE PET/CT imaging within 1 week (median: 3 days; range: 1-7 days). The diagnostic performance of the two imaging modalities was assessed and compared on a per-patient, per-lesion and per-region basis. Furthermore, the differences in patient characteristics between groups with and without changes in clinical management decisions were analyzed. Group differences were evaluated using the independent samples t-test, χ2 test, Fisher's exact test, and Mann-Whitney U test. RESULTS: 40 patients (40/41, 98%) were confirmed with CNS metastases. The mean age at CNS metastases was 63 months (range: 8-122 months). 68Ga-DOTATATE PET/CT exhibited superior performance compared with 123I-MIBG SPECT/CT in detecting CNS metastases on a per-patient, per-lesion and per-region basis. Additionally, the results of 68Ga-DOTATATE PET/CT led to changes in clinical management in 51% (21/41) of patients, primarily due to new or unexpected findings compared with those obtained using 123I-MIBG SPECT/CT. CONCLUSIONS: 68Ga-DOTATATE PET/CT demonstrated excellent diagnostic performance in NB and GNB patients with CNS metastases. Moreover, the findings from 68Ga-DOTATATE PET/CT led to a modification of the therapeutic management in 51% of patients.
引用
- Li S, Zhou Z, Wang X, et al. A head-to-head prospective comparative analysis of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT/CT in central nervous system metastases of neuroblastoma and ganglioneuroblastoma. Eur J Nucl Med Mol Imaging. 2025. PMID: 40637785. doi:10.1007/s00259-025-07440-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。